HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
- Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling; Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics Group
- Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling; Univ. of Edinburgh, Scotland (United Kingdom). Center for Immunity
- Heidelberg Univ. (Germany). Cetner for Modeling and Simulation in the Biosciences
- Loyola Univ. Medical Center, Maywood, IL (United States). The Program for Experimental and Theoretical Modeling
- Univ. of Sao Paulo Hospital das Cinicas (Brazil)
- Alphabio Lab., Marseille (France)
- European Hospital, Marseille (France). Internal Medicine and Infectious Disease
- Saint Joseph Hospital, Marseille (France). Division of Hepatology
- CH Hyeres (France). Division of Hepatology
- Alphabio Lab., Marseille (France); European Hospital, Marseille (France). Internal Medicine and Infectious Disease
Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether early response kinetics can provide the basis to individualize therapy to achieve optimal results while reducing duration and cost. 58 chronic HCV patients were treated with 12-week sofosbuvir + simeprevir (n = 19), sofosbuvir + daclatasvir (n = 19), or sofosbuvir + ledipasvir in three French referral centers. HCV was measured at baseline, day 2, every other week, EOT and 12 weeks post EOT. Furthermore, mathematical modeling was used to predict the time to cure, i.e., <1 virus copy in the entire extracellular body fluid. All but one patient who relapsed achieved SVR. Mean age was 60 ± 11 years, 53% were male, 86% HCV genotype-1, 9% HIV coinfected, 43% advanced fibrosis (F3), and 57% had cirrhosis. At weeks 2, 4 and 6, 48%, 88% and 100% of patients had HCV <15 IU/ml, with 27%, 74% and 91% of observations having target not detected, respectively. Modeling results predicted that 23 (43%), 16 (30%), 7 (13%), 5 (9%) and 3 (5%) subjects were predicted to reach cure within 6, 8, 10, 12 and 13 weeks of therapy, respectively. The modeling suggested that the patient who relapsed would have benefitted from an additional week of sofosbuvir + ledipasvir. Adjusting duration of treatment according to the modeling predicts reduced medication costs of 43–45% and 17–30% in subjects who had HCV <15 IU/ml at weeks 2 and 4, respectively. Finally, the use of early viral kinetic analysis has the potential to individualize duration of DAA therapy with a projected average cost saving of 16–20% per 100-treated persons.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE; National Institutes of Health (NIH)
- Grant/Contract Number:
- AC52-06NA25396; 1698:BB/L001330/1
- OSTI ID:
- 1334130
- Alternate ID(s):
- OSTI ID: 1467524
- Report Number(s):
- LA-UR-15-27222
- Journal Information:
- Journal of Hepatology, Vol. 64, Issue 6; ISSN 0168-8278
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents